Pharmacy Drugs
Recent Posts
- Malignant Brain Tumors: Chemotherapy Alone Is Just As Effective As Radiation / New Positive Prognostic Factor Found
- Positive Interim Data From Minnow Medical Peripheral Artery Disease Trial Presented At TCT 2009 Conference
- Intercept Pharmaceuticals’ FXR Agonist INT-747 Meets Primary Endpoint In A Phase II Clinical Trial In Type 2 Diabetic Patients
- Largest Clinical Trial To Test Benefits Of Aspirin In Australia
- University Of Florida To Receive $29.5 Million In Recovery Act Funds To Begin Study Of Whether Exercise Prevents Disability In Older Adults
Random Posts
- Targeted Cancer Treatment Following Breakthrough In Radiotherapy
- Experimental Vaccine Shows Promise In Treating Precancerous Vulvar Growths, Study Says
- Limited-Option HIV Drug Approved for Expanded Use
- Synexus Leads The Way In South Africa With Vital Paediatric Vaccines Trial
- Shire Selects SAS(R) Drug Development To Handle Clinical Trials Data
- FDA Approves Generic Prescription-Only Version Of Plan B Emergency Contraceptive For Women Ages 17 And Under
- Fingolimod And Cladribine: Two New Oral Substances Show Promising Results In Current Clinical Trials For MS Therapy
- Large, Long-Term Study Shows Avandia Has No Increased Overall Cardiovascular Risk Compared To Other Commonly Used Diabetes Medicines
- BioCis Pharma Reports Positive Phase IIa Clinical Results In Atopic Dermatitis
- FDA Okays Ankle Replacement Device
DIA 45th Annual Meeting Features Sessions Highlighting Wyeth V. Levine And Pandemic Influenza
Posted by: admin in Pharmacy Drugs on October 11th, 2009
The Drug Information Association (DIA) 45th Annual Meeting is the biopharmaceutical industry’s largest and longest running global, multidisciplinary conference featuring sessions and preconference tutorials on issues affecting drug discovery and development, including two timely sessions reflecting the state of today’s global biopharmaceutical environment.
The public policy/law track features a special session on org/DIAHOME/FlagshipMeetings/SearchSesTut.aspx?productID=20655&rpex=N&kw=Labeling%20Risk:%20Practical%20Approaches%20after%20Wyeth%20v.%20Levine&ia=ALL&meetingid=17194″ target=”_blank” rel=”nofollow”>Labeling Risk: Practical Approaches after Wyeth v. Levine (June 22; 1:30 - 3:00 pm).
In March 2009, the Supreme Court ruled in Wyeth v. Levine that pharmaceutical companies are not necessarily shielded from failure to warn product liability lawsuits in state courts when the US FDA has determined that approved labeling appropriately explains risk information. This session will explore practical approaches pharmaceutical companies should consider when disseminating risk information to minimize failure to warn liability and to maximize the possibility such liability is preempted.
“We will delve deep into the legal benefits of preemptions, describe regulatory and documentation strategies that maximize the availability of preemption in failure-to-warn lawsuits, and identify effective risk communication strategies,” says Session Chair Patrick C O’Brien, JD, PharmD, Partner, Burke O’Neil LLC, United States.
Speakers include:
- John B Moriarty, JD, Senior Vice President, Elan Pharmaceuticals, United States
- Sandra A. Milligan, JD, MD, Executive Director, Amgen Inc., United States
- Mary K. Pendergast, JD, LLM, President, Pendergast Consulting, United States
This year’s biotechnology track includes atimely session on Regulatory Methods to Facilitate the Approval of Biological Products to Address Pandemic Influenza (June 22, 1:30 - 3:00 pm).
This session incorporates descriptions of novel regulatory mechanisms for vaccine approval with a discussion of successful applications for pandemic influenza.
“This must-attend session will attempt to identify novel regulatory approaches to vaccine approval, industry approaches toward interactions with the FDA, and novel biochemical methods for the development of vaccines,” explains Session Chair Richard M Lewis, PhD, CEO, Access BIO, United States.
Speakers include:
- Jean L Hu-Primmer, MS, Program Manager, Pandemic and Emerging Threat Preparedness, OD, CBER, USFDA
- John Purves, PhD, Head of Sector, Quality of Medicines, European Medicines Agency
- Ozzie Berger, Senior Director and Head, Influenza Vaccines, US Regulatory Affairs, Biologicals, GlaxoSmithKline
Source
The Drug Information Association (DIA)
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URL
Leave a comment
You must be logged in to post a comment.